Remdesivir


Shedding light on some peer-reviewed randomized control trials conducted so far with this anti viral drug touted for use in alleviating intensive care in severe COVID-19 patients.

On May 22, 2020 the New England Journal of Medicine published a preliminary report of a double-blind randomized, placebo-controlled trial of intravenous remdesivir.

They concluded that remdesivir is superior to placebo in shortening recovery time in adults hospitalized with COVID-19. A total of 1063 patients underwent randomization.

On April 29, 2020 the Lancet published a double-blind randomized, placebo-controlled multicentre trial of intravenous remdesivir.

237 patients were studied, in which no statistically significant clinical benefit was ascertained, however a numerical reduction in time to clinical improvement was observed in hospitialized COVID-19 patients.

Medical

Dr Babu View All →

Radiologist l Cyclist l Blogger

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: